CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound represented by formula 1:



(1)

wherein

R^1 is selected from the group consisting of H, halogen, (C_{1-4})alkyl, $O(C_{1-4})$alkyl, and haloalkyl;

R^2 is H or Me;

R^3 is H or (C_{1-4})alkyl;

R^4 is H or (C_{1-4})alkyl;

R^5 is (C_{1-4})alkyl, (C_{1-4})alkyl(C_{3-7})cycloalkyl, or (C_{3-7})cycloalkyl; and

W is selected from:



wherein,

a) one of **Y** is SO_2 and the other **Y** is NR^6, provided that both are not the same, wherein R^6 is selected from the group consisting of: H, $C(O)O(C_{1-4})$alkyl, (C_{1-4}) alkyl or (C_{1-4}) alkyl substituted with either a pyridinyl-N-oxide or $C(O)OR^8$ wherein R^8 is H or (C_{1-4}) alkyl; and each R^9 is independently H or (C_{1-4}) alkyl; and

b) **E** is $CR^{10}R^{10}$ wherein each R^{10} is independently H or (C_{1-4}) alkyl, J is CH_2 and the dotted line represents a single bond; or

c) **E** and **J** are both CR^{11} wherein R^{11} is H or (C_{1-4}) alkyl and the dotted line represents a double bond; or

W is selected from:



wherein,

m is 1 or 2,

R^{12} is H or $C_{(1-4)}$ alkyl,

R^{13} is H or (C_{1-4}) alkyl, and

Z is **O** or **Z** is NR^{14} wherein R^{14} is H or (C_{1-4}) alkyl; or

W is selected from a group of aromatic radicals consisting of:





,


and


wherein $\mathbf{R}^{15}$ is (C_{1-4}) alkyl or CF_3, and n is the integer 0, 1 or 2, or a pharmaceutically acceptable salt~~,~~ or ester ~~or a prodrug~~ thereof.

Claim 2 (original): The compound according to claim 1, wherein $\mathbf{R}^1$ is selected from the group consisting of: H, Cl, F, (C_{1-4}) alkyl and CF_3; $\mathbf{R}^2$, $\mathbf{R}^3$ and $\mathbf{R}^4$ is each independently H or Me; $\mathbf{R}^5$ is ethyl or cyclopropyl;

W is:



wherein **Y** is SO_2 and the other **Y** is $N\mathbf{R}^6$, provided that both are not the same, $\mathbf{R}^6$ is H, C(O)OMe, C(O)OEt, (4-pyridinyl-N-oxide)methyl, $CH_2C(O)OH$, $CH_2C(O)OMe$, $CH_2C(O)OEt$ or $CH_2C(O)OCMe_3$, and each $\mathbf{R}^9$ is independently H or Me; or



wherein **E** is $CR^{10}R^{10}$ wherein each of $\mathbf{R}^{10}$ is independently H or Me, **J** is CH_2 and the dotted line represents a single bond; or both **E** and **J** are $C\mathbf{R}^{11}$ wherein $\mathbf{R}^{11}$ is H or Me and the dotted line represents a double bond; one of **Y** is SO_2 and the other **Y** is $N\mathbf{R}^6$ wherein $\mathbf{R}^6$ is hydrogen or methyl; or



,


,


,


.

,



wherein $\mathbf{R}^{15}$ is Me or Et, and n is 0 or 1.

Claim 3 (original): The compound according to claim 2, wherein $\mathbf{R}^{15}$ is Me.

Claim 4 (original): The compound according to claim 3, wherein $\mathbf{R}^{1}$ is H, Cl, F and Me; $\mathbf{R}^{2}$ is H or Me;

W is:



wherein **Y** is SO_2 and the other **Y** is $N\mathbf{R}^{6}$, provided that both are not the same, $\mathbf{R}^{6}$ is H, C(O)OEt, (4-pyridinyl-N-oxide)methyl, $CH_2C(O)OH$, $CH_2C(O)OMe$, $CH_2C(O)OEt$ or $CH_2C(O)OCMe_3$, and each $\mathbf{R}^{9}$ is independently H or Me.

Claim 5 (original): The compound according to claim 4, wherein **R**^{3} is Me, **R**^{6} is H, C(O)OEt or (4-pyridinyl-N-oxide)methyl, and **W** is:



Claim 6 (original): The compound according to claim 4, wherein **W** is:



wherein one **Y** is SO_2 and the other **Y** is N**R**^{6}, provided that both are not the same, **R**^{6} is H, C(O)OEt, $CH_2C(O)OH$, $CH_2C(O)OCMe_3$, (4-pyridinyl-N-oxide)methyl; and each **R**^{9} is independently H or Me.

Claim 7 (original): The compound according to claim 6, wherein **R**^{6} is H and each **R**^{9} is Me.

Claim 8 (cancelled)

Claim 9 (cancelled)

Claim 10 (cancelled)

Claim 11 (currently amended): A pharmaceutical composition for the treatment ~~or prevention~~ of HIV infection, comprising a compound of formula 1 according to claim 1, or a pharmaceutically acceptable salt~~,~~ or ester ~~or prodrug~~ thereof, in combination with a pharmaceutically acceptable carrier.

Claim 12 (currently amended): A method for the treatment ~~or prevention~~ of HIV infection, comprising administering to a patient an HIV inhibiting amount of a compound of formula 1 according to claim 1, or a pharmaceutically acceptable salt~~,~~ or ester ~~or prodrug~~ thereof.

Claim 13 (currently amended): A method for the treatment ~~or prevention~~ of HIV infection, comprising administering to a patient an HIV inhibiting amount of a pharmaceutical composition according to claim 11.

Claim 14 (original): A process for producing a compound of formula 1 according to claim 1, comprising the step:

- coupling a compound of formula 2:



(2)

wherein **R**^{1}, **R**^{2}, **R**^{3}, **R**^{4}, and **R**^{5} are as defined in claim 1, with a phenolic derivative selected from:



,



,



,



,



wherein PG^1 is a nitrogen protecting group and PG^2 is a carboxy protecting group, said protecting groups being removable under mildly acidic, mildly alkaline or reductive conditions, and **R^6**, **R^9**, **R^{10}**, **R^{11}**, **R^{12}**, **R^{13}**, **R^{14}**, **R^{15}**, m, n, and **Z** are as defined in claim 1.

Claim 15 (original): The process according to claim 14, wherein said nitrogen protecting group is selected from: alkyl esters; aralkyl esters; and esters that can be cleaved by mild base treatment or mild reductive means.

Claim 16 (original): The process according to claim 14, wherein said carboxy protecting group is selected from: Boc (*tert*-butyloxycarbonyl) and alkyl carbamates.

Claim 17 (original): An intermediate compound of formula 2:



(2)

wherein **R**^{1}, **R**^{2}, **R**^{3}, **R**^{4}, and **R**^{5} are as defined in claim 1.